NeuroPace (NPCE) Research & Development (2020 - 2026)

NeuroPace has reported Research & Development for 7 years, with the latest figure at $12.1 million in Q2 2026.

• On a quarterly basis, Research & Development rose 5.53% year-over-year to $12.1 million in Q2 2026; TTM through Jun 2026 was $47.2 million, a 11.49% increase from a year earlier, with the FY2025 full-year figure at $46.6 million, up 17.42% from the prior year.
• Research & Development was $12.1 million for Q2 2026 at NeuroPace, up from $11.6 million in the prior quarter.
• The five-year high for Research & Development was $12.6 million in Q3 2025, with the low at $4.8 million in Q3 2023.
• Average Research & Development over 5 years is $8.2 million, with a median of $7.8 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2024: Research & Development retreated 14.54% in 2023, then soared 107.07% in 2024.
• Over 5 years, Research & Development stood at $5.1 million in 2022, then advanced by 5.66% to $5.4 million in 2023, then soared by 85.07% to $10.0 million in 2024, then increased by 9.9% to $10.9 million in 2025, then gained by 10.86% to $12.1 million in 2026.
• The last three Research & Development figures came in at $12.1 million (Q2 2026), $11.6 million (Q1 2026), and $10.9 million (Q4 2025), per Business Quant data.